An advisory committee to the Food and Drug Administration (FDA) has voted in favor of adding the peptide BPC-157 to a drug compounding list, a decision that could lead to its wider availability to patients with a prescription. The Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with one abstention on Thursday to recommend the inclusion of BPC-157. This decision is not final and requires approval from the FDA itself.
BPC-157, a peptide that has gained popularity online for its purported ability to aid gut and tissue healing, is currently often found on the black and grey markets. The committee's vote represents a step toward a more regulated pathway for such substances, which would allow them to be compounded rather than undergoing the full FDA approval process. This is the first of seven peptides the committee is reviewing, with further discussions and votes anticipated.
FDA staff scientists raised concerns during the meeting regarding the general scarcity of quality data to support the safety and effectiveness of BPC-157. Committee members who voted in favor cited minimal perceived risks, while opponents highlighted potential safety and efficacy issues. They also expressed apprehension that listing the peptide could create a misleading impression of rigorous FDA evaluation, similar to that of fully approved drugs.
Peptides are short chains of amino acids. Their popularity has surged online, with proponents suggesting benefits ranging from muscle building to metabolism enhancement. However, much of the existing research has been conducted on rodents, and results from these studies do not always translate to humans.
This development occurs amidst scrutiny of the PCAC, with criticism leveled at alleged financial conflicts of interest among some newly appointed members, particularly in light of Health and Human Services Secretary Robert F. Kennedy Jr.'s promotion of peptide use.